RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
Altimmune, Inc. · Alcohol Liver Disease
Phase 2
Recruiting
100
2026-03
Evidence dashboardStudies since 2007Updated Jul 31, 2026
PemvidutideClinical Trials.
A source-linked view of every Pemvidutide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 15
- Recruiting
- 1
- Completed
- 11
- Terminated
- 2
- Results posted
- 4
- Average enrollment
- 86
- Countries
- 3
- Highest phase
- Phase 2
Largest indexed study
391 participants · NCT05295875 →Developer / research origin
Altimmune
Evidence summary
Activity is not efficacy.
Pemvidutide appears in 15 indexed studies: 1 recruiting, 11 completed and 4 with registry results posted. The highest registered development stage in this snapshot is Phase 2. These counts measure registry activity; they do not establish that Pemvidutide is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
NCT IDStudyPhase / statusEnrollmentUpdated
NCT IDStudyPhase / statusEnrollmentUpdated
RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
Altimmune, Inc. · Alcohol Use Disorder (AUD)
Phase 2
Completed
100
2026-07
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
Altimmune, Inc. · Non-Alcoholic Steatohepatitis (NASH)
Phase 2
Completed
212
2026-05
ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability
Altimmune, Inc. · Obesity · Nonalcoholic Steatohepatitis
Phase 1
Completed
100
2025-06
Pemvidutide (ALT-801) DDI Study in Healthy Volunteers
Altimmune, Inc. · NASH - Nonalcoholic Steatohepatitis
Phase 1
Completed
40
2025-06
ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)
Altimmune, Inc. · Type 2 Diabetes
Phase 1
Completed
55
2025-06
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Altor BioScience · Transitional Cell Carcinoma of Bladder · Urethra Cancer
Phase 1 / Phase 2
Completed
68
2024-06
Showing 6 of 11 studies
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Altor BioScience · Non-muscle Invasive Bladder Cancer
Phase 1 / Phase 2
Terminated
12
2024-07
QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Altor BioScience · Relapsed or Refractory Multiple Myeloma
Phase 1 / Phase 2
Terminated
6
2024-06
ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia
Altor BioScience · Acute Myeloid Leukemia
Phase 1
Withdrawn
0
2014-01
Full study index
Search Pemvidutide trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
15 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 41237796 ↗Noureddin M, Harrison SA, Loomba R, Alkhouri N, Chalasani N, Sheikh MY, Tomah S, Gutierrez JA, Urbina S, Suschak JJ, Brown R, Odili O, Yang J, Keeton S, Neff G, Mena E, Roberts MS, Browne SK, Harris MS. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet. 2025 Dec 6;406(10520):2644-2655. doi: 10.1016/S0140-6736(25)02114-2. Epub 2025 Nov 11.Linked from NCT05989711PMID 39002641 ↗Harrison SA, Browne SK, Suschak JJ, Tomah S, Gutierrez JA, Yang J, Roberts MS, Harris MS. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. J Hepatol. 2025 Jan;82(1):7-17. doi: 10.1016/j.jhep.2024.07.006. Epub 2024 Jul 11.Linked from NCT05006885PMID 41113119 ↗Browne SK, Suschak JJ, Tomah S, Gutierrez JA, Yang J, Georges B, Roberts MS, Harris MS. Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. JHEP Rep. 2025 Jun 18;7(11):101483. doi: 10.1016/j.jhepr.2025.101483. eCollection 2025 Nov.Linked from NCT05292911PMID 21994418 ↗Fishman MN, Thompson JA, Pennock GK, Gonzalez R, Diez LM, Daud AI, Weber JS, Huang BY, Tang S, Rhode PR, Wong HC. Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15;17(24):7765-75. doi: 10.1158/1078-0432.CCR-11-1817. Epub 2011 Oct 12.Linked from NCT00496860
Related pages
Keep researching Pemvidutide.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.